Biomedical Innovation: Who pays for the cure?
In 2013, the FDA approved Sovaldi, a groundbreaking cure for the once incurable disease, chronic hepatitis C. Sovaldi’s launch broke blockbuster drug barriers, bringing in $2.27 billion in 2013 Q1 sales alone.
